Sanofi (NYSE:SNY) : The money flow is calculated as the dollar value of composite uptick trades minus the dollar value of downtick trades, which was negative (0.91 million) in Sanofi (NYSE:SNY). On Wednesday, The value of composite uptick trades was $0.87 million, whereas, the value of composite downtick trades was $1.78 million and the ratio between the two was 0.49, indicating selling on strength. Traders involved in block trades booked profits in their holdings as seen in the transactions on downticks valued at $0.71 million. The negative money flow of ($0.71 million) shows selling on strength. Sanofi (NYSE:SNY) gained $0.78 intraday at $41.33 and registrered 1.92% for the week.
Currently the company Insiders own 1% of Sanofi shares according to the proxy statements. Institutional Investors own 9.13% of Sanofi shares.
The company shares have dropped -18.51% from its 1 Year high price. On Aug 10, 2015, the shares registered one year high at $54.98 and the one year low was seen on Jun 16, 2016. The 50-Day Moving Average price is $39.94 and the 200 Day Moving Average price is recorded at $40.81. Sanofi (NYSE:SNY): During Wednesdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $41.67 and $41.08 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $41.68. The buying momentum continued till the end and the stock did not give up its gains. It closed at $41.26, notching a gain of 1.75% for the day. The total traded volume was 3,413,676 . The stock had closed at $40.55 on the previous day.
Sanofi SA is a healthcare company focused on patient needs and engaged in the research, development, manufacture and marketing of healthcare products. The Company is organized around three principal activities: Pharmaceuticals, Human Vaccines via Sanofi Pasteur, and Animal Health via Merial. The Company invests in emerging markets, diabetes solutions, vaccines, consumer health care, animal health, genzyme and other products. The emerging markets platform includes products from all three of the Companys principal activities. Under the Companys Pharmaceuticals business, products are grouped into the key fields of diabetes solutions, rare diseases, multiple sclerosis, oncology, thrombosis and cardiovascular disease prevention, nephrology and bio-surgery. The Human Vaccines activity is operated through Sanofi Pasteur. The Animal Health activity is carried out through Merial.